Table 4 In vivo tumourigenicity experiment of putative lung CSCs and non-putative CSCs
Cell type | Cell number injected | Tumour incidence | Tumour size (average) (cm) |
|---|---|---|---|
A549 Parental | 20,000 | 3 / 3 | 0.89 |
A549 CD166+/CD44+ | 20,000 | 3 / 3 | 1.00 |
A549 CD166−/CD44− | 20,000 | 2 / 3 | 0.83 |
A549 CD166+/EpCAM+ | 20,000 | 3 / 3 | 1.18 |
A549 CD166−/EpCAM− | 20,000 | 2 / 3 | 0.70 |
H2170 Parental | 20,000 | 3 / 3 | 1.28 |
H2170 CD166+/EpCAM+ | 20,000 | 3 / 3 | 1.39 |
H2170 CD166−/EpCAM− | 20,000 | 2 / 3 | 0.89 |
Control (media + matrigel) | 20,000 | 0 / 3 | 0 |